Endothelial cell Pannexin1 modulates severity of ischemic stroke by regulating cerebral inflammation and myogenic tone

Miranda E Good,1 Stephanie A. Eucker,2 Jun Li,3 Hannah M. Bacon,1 Susan M. Lang,1 Joshua T. Butcher,1 Tyler J. Johnson,1 Ronald P. Gaykema,1 Manoj K. Patel,3 Zhiyi Zuo,3 and Brant E. Isakson1,4

1Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA. 2Division of Emergency Medicine, Department of Surgery, Duke University, Durham, North Carolina, USA. 3Department of Anesthesiology and 4Department of Molecular Physiology and Biophysics, University of Virginia School of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA.

Introduction

Stroke is the fourth leading cause of death in the US, and each year, approximately 15 million people experience an acute ischemic stroke worldwide (1). Although the incidence of acute ischemic stroke is remarkably high, acute pharmacological treatment remains limited to thrombolytic therapy. Thrombolytic agents such as tissue plasminogen activator (tPA) break down vascular obstructions but do not aim to reduce the extent of the injury following reperfusion. Additionally, the short window of effectiveness for administration of tPA drastically limits its therapeutic potential (2). Identification of novel therapeutic targets is necessary to improve patient outcomes following an ischemic stroke. Recently, pannexins have emerged as potentially novel channels within multiple cell types of the brain that might provide such a target for improving stroke outcome.

Pannexins are a recently discovered family of membrane channels whose primary function appears to be the regulated release of purines from intracellular stores (3). There are 3 known pannexin isoforms, Pannexin1 (Panx1), Panx2, and Panx3. The Panx1 isoform is found in endothelial cells (ECs) throughout the arterial tree, as well as in smooth muscle cells (SMCs) of arteries and arterioles less than 300 μm in diameter (4). Although Panx1 continues to be discovered in new locations, a complete understanding of the role(s) these channels play in regulating vascular function is currently lacking.

Panx1 is present in both the neurons and the cerebral vasculature of the rat (5). Deletion or blocking of pannexins has been shown to significantly improve outcome following middle cerebral artery occlusion (MCAO) (6–8); nevertheless, these studies have important limitations. Systemically administered...
pharmacological inhibitors of pannexins significantly reduced infarct size following MCAO/reperfusion (6, 8). In addition, global deletion of Panx1 and Panx2 reduced infarct volume following permanent MCAO (7). However, global deletion of Panx1 was also shown to upregulate Panx3 in the vasculature, indicating a potential compensatory mechanism (9). Furthermore, the focus of these studies was on the pannexins found in neurons and the effects of ATP on neuronal function. While these data point to pannexins playing a significant role in determining stroke outcome, the studies globally affected pannexin channels within the brain, including those in the vascular cells, indicating the need to explore the role of Panx1 specifically in the cerebral vasculature.

Purine release by Panx1 channels has been shown to regulate vascular function in both venous and arterial vessels (10, 11). For instance, endothelial Panx1 regulates TNF-α–induced leukocyte adhesion and emigration in venules (11). TNF-α is released following an ischemic stroke, and treatment with an anti–TNF-α antibody or inhibition of neutrophil infiltration improves stroke outcome in mice, indicating a role of inflammation in determining severity of stroke (12, 13).

In addition to the venous inflammatory pathway, upstream regulation of cerebral blood flow (CBF) by Panx1 may also impact stroke outcome. Restoring adequate CBF is vital for recovery following acute ischemic stroke (14–16). CBF is largely regulated by myogenic reactivity, in which arteries constrict in response to increased luminal pressure. Myogenic reactivity is altered in pathophysiological states such as cerebral ischemia (17), so understanding its mechanisms is crucial. Recent reports suggest that myogenic reactivity is a purinergic-dependent mechanism, specifically through P2Y receptors that are activated by extracellular purines (e.g., ATP) (14, 18, 19). Therefore, mechanisms that couple the release of ATP with activation of P2Y receptors may be targets for pharmacological interventions to improve CBF regulation in disease states.

In this study, we reveal a potentially novel mechanism by which vascular Panx1 regulates stroke outcome in mice. We demonstrate that deletion of endothelial, but not smooth muscle, Panx1 significantly improves stroke outcome following cerebral ischemia/reperfusion injury by reducing infiltration of circulating leukocytes and reducing the development of myogenic tone in cerebral arteries. Furthermore, by showing the absence of Panx1 effects on peripheral mesenteric artery myogenic tone development, we demonstrate that endothelial Panx1 regulation of myogenic tone is unique to the cerebral arteries.

Results

Endothelial Panx1 protects against cerebral ischemia/reperfusion injury. Panx1 is expressed in multiple cell types within the brain (5, 20, 21). Here, we demonstrate Panx1 staining throughout the brain (Figure 1A), and we find high expression within the neurons (Figure 1B). Posterior cerebral arteries (PCAs) isolated from control mice had Panx1 expression in EC and SMC (Figure 1, C and F). Secondary and isotype controls were negative for staining (Figure 1, D and E). Mice with activated Cre specific to EC or SMC have reduced staining in their respective cell types (Figure 1, G and H). To determine the potential role of vascular Panx1 in regulating vascular response to ischemic stroke, we performed a 90-minute unilateral MCAO followed by 24-hour reperfusion in transgenic mice lacking Panx1 in either SMCs (SMC Panx1 Δ/Δ; Figure 2, B and C) or ECs (EC Panx1 Δ/Δ; Figure 2, E and G), and their controls (SMC Panx1 β/β or EC Panx1 fl/fl, respectively, and Cre− Panx1 fl/fl [tamoxifen control]; Figure 2, A, D, and F) and stained with 2,3,5-triphenyltetrazolium chloride (TTC) to quantify infarct volume (Figure 2, A–F). Deletion of SMC Panx1 did not change the infarct volume following the ischemic stroke; however, deletion of EC Panx1 significantly mitigated the infarct volume (Figure 2, C and G).

Infiltration of circulating leukocytes is significantly reduced in mice lacking endothelial Panx1. EC Panx1 has previously been shown to regulate TNF-α–mediated leukocyte rolling and adhesion, and inflammation is known to occur following an ischemia/reperfusion insult in the brain (11, 22–24). Thus, we examined the infiltration of circulating leukocytes into ischemic brain tissue of Panx1 transgenic mice using flow cytometry (Figure 3, D and E). EC Panx1 fl/fl mice showed an increased infiltration of leukocytes, which express high levels of CD45 (CD45hi), in the ischemic hemisphere compared with the contralateral hemisphere (Figure 3A). Of these infiltrating leukocytes, Ly6G+ cells (neutrophils) were the predominant cell type (Figure 3B), whereas CD11b and Ly6C double-positive cells (CD11b+/Ly6C+; monocytes) were minimally present (Figure 3C). Deletion of EC Panx1 significantly reduced the total percentage of infiltrating leukocytes but did not significantly change the relative amounts of the 2 specific types of leukocytes examined. Reduction of MCA blood flow in these leukocyte infiltration studies was verified using laser
Doppler measurements of the MCA during the 90-minute ischemic injury (change in blood flow through the MCA for EC Panx fl/fl mice, −62.85% ± 7.30%; EC Panx Δ/Δ mice, −61.41% ± 7.66%).

Pharmacological inhibition of Panx1 reduces development of cerebral artery myogenic tone. In contrast to venous-circulation ischemic responses, arterial function can also impact recovery following cerebral ischemia/reperfusion injury, particularly by regulating CBF recovery through changes in myogenic tone. Given the dependence of purinergic signaling for myogenic tone development (18, 19), we first treated mouse cerebral arteries with apyrase to degrade extracellular purines. Here, we observed that apyrase significantly reduced myogenic tone in C57Bl/6 mouse cerebral arteries (Figure 4A) by altering the active diameter (Figure 4B), whereas the passive diameter was not affected by apyrase treatment (Figure 4C). Treatment with carbenoxolone similarly reduced the development of myogenic tone by diminishing the active diameter without changing the passive diameter of cerebral arteries (Figure 4, A–C). Carbenoxolone is a nonspecific inhibitor of Panx1, with other targets including the related connexin-based channels; therefore, we also examined treatment with spironolactone, a recently discovered inhibitor of Panx1 channels, that does not target connexin- or other Panx isoform–based channels (25). Treatment with spironolactone resulted in a similar reduction of cerebral myogenic tone development (Figure 4, D–F). These data suggest that Panx1 and extracellular purines can regulate cerebral myogenic tone without altering the passive properties of the cerebral vessels.

Genetic deletion of endothelial Panx1 reduces development of cerebral artery myogenic tone. Next, we examined the development of myogenic tone in cerebral arteries of EC Panx1 Δ/Δ and SMC Panx1 Δ/Δ mice (Figure 5). Deletion of EC Panx1 resulted in decreased myogenic tone development (Figure 5A), similar to that seen in pharmacological experiments, with an increase in active diameter (Figure 5B) and no change in passive diameter (Figure 5C). In addition to the reduced myogenic tone development in the PCA from EC Panx1 Δ/Δ mice, a similar reduction is observed in their MCA (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.96272DS1). However, deletion of SMC Panx1 did not alter the development of myogenic tone in cerebral arteries (Figure 5, D and E). These data, coupled with the data above, suggest that EC Panx1 may regulate severity of cerebral ischemia/reperfusion injury.

Figure 1. Panx1 is expressed in EC and SMC of cerebral arteries with successful knockdown in EC and SMC transgenic mice. In all sections, Panx1 (Panx1-CT antibody) was stained in red and nuclei (DAPI) in blue. (A) Low-magnification view of brain section. Arrow indicates cerebral artery in field of view. (B) Zoomed-in cross section of the somatosensory cortex neurons sections were stained for Panx1 and neurons using NeuN antibody (green). (C) Isolated control PCA sections were collected from Panx1 fl/fl (control) at low magnification, as well as (D) secondary antibody only and (E) rabbit IgG. (F) High magnification of control PCA and PCA from mice that had genotypes of SMC Panx1 Δ/Δ (G), and EC Panx1 Δ/Δ (H). In D and E, the autofluorescence of the internal elastic lamina is in green and separates the EC (E) and SMC (S) layers. In F–H the separation between EC and SMC, the IEL, is indicated by a dotted line. Asterisks indicate lumen of artery in each image. (A and B) Scale bars: 100 μm. (C–E) Scale bar: 20 μm. (F–H) Scale bar: 10 μm.
through dual mechanisms of increased infiltration of circulating leukocytes into brain tissue through veins and increased myogenic tone in cerebral arteries.

Previous work has demonstrated that mesenteric arteries also utilize purinergic signaling to regulate myogenic tone, and Panx1 is expressed within the ECs of mesenteric arteries (11, 26, 27). In concordance with those experiments, we found that carbenoxolone treatment, which inhibits both Panx1 and Cx43 channels, significantly reduced myogenic tone development in third-order mesenteric arteries (Figure 6, A–C), whereas spironolactone treatment, which does not inhibit Cx43 channels (25), did not impact mesenteric myogenic tone development (Figure 6, D–F). In agreement with our pharmacological data, deletion of EC Panx1 did not alter development of myogenic tone in mesenteric arteries (Figure 6, G–I). This finding is in line with the previous report that mesenteric myogenic tone development may work through Cx43 (27). In fact, global Panx1-KO mice show no differences in myogenic tone development in mesenteric arteries, while adrenergic-mediated vasoconstriction is ablated, as described previously (10, 27).

**Discussion**

As tPA administration remains the only approved pharmacological intervention for ischemic stroke in the acute period, a medical need exists for novel therapeutic targets (1). Purinergic signaling has been demonstrated to have important effects on stroke outcomes (28, 29). Panx1 channels are potentially novel purine release channels that are expressed on multiple cell types in the brain, including cerebral ECs and SMCs, as we demonstrate here (5, 20, 21). Previous studies showed that global deletion of Panx1, although leading to compensatory changes of other pannexin isoforms, significantly reduced infarct size following ischemic stroke (6–9). Similar effects were observed using pharmacological pannexin inhibitors, including systemically administered probenecid, a nonspecific inhibitor of pannexins, and a pannexin C-terminal mimetic peptide (6–9). Thus, while pannexins were implicated in improving overall stroke outcomes, these studies lacked cell type–specific targeting of Panx1 and mechanisms contributing to the stroke phenotype.
Therefore, we specifically explored the contributions of SMC and EC Panx1 on the severity of stroke outcome in mice. Here, we demonstrate for the first time to our knowledge that deletion of Panx1 from ECs, but not SMCs, significantly reduces infarct volume following a 90-minute cerebral ischemia and 24-hour reperfusion injury, an effect that is independent of tamoxifen. These effects appear to be mediated through the dual mechanisms of reduced leukocyte infiltration into ischemic brain tissue, as well as reduced development of cerebral arterial myogenic tone.

Endothelial Panx1 and purine release from venous ECs have been implicated in regulation of inflammation following injury. Following TNF-α application, ATP release and subsequent leukocyte adhesion along venous ECs were shown to be Panx1 dependent (11). In addition, TNF-α–induced leukocyte adhesion and emigration were significantly reduced in the cremaster vasculature of mice lacking endothelial Panx1 (11). In the context of ischemic stroke, TNF-α secretion is enhanced following stroke onset, while blocking TNF signaling pathways improved stroke outcome (12, 23, 24). Studies supporting the role of purines in stroke found that deletion of ectonucleotidases, such as CD39 and CD73, resulted in larger infarcts following a cerebral ischemic insult (28, 29). The increased infarct volume correlated strongly with an increase

Figure 3. Brain tissue infiltration of leukocytes is significantly reduced in EC Panx1 Δ/Δ mice following stroke. Following a 90-minute MCAO and 24-hour reperfusion, ischemic and contralateral hemispheres were perfused and isolated from EC Panx1 fl/fl and EC Panx1 Δ/Δ mice and stained for leukocyte markers for flow cytometry analysis. Differences in the percentages of total infiltrated leukocytes (CD45hi), neutrophils (CD45hi/Ly6G+), or monocytes (CD45hi/CD11b+/Ly6C+) between the ischemic and contralateral hemispheres were calculated (A–C). Representative flow cytometry graphs of the contralateral (D) and ischemic (E) hemispheres of an EC Panx1 fl/fl mouse are shown, along with gating strategies. Live cells (red box) were further analyzed for expression of CD45. Intermediate expression of CD45 is indicative of microglia cells (black box), while cells expressing high levels of CD45 (green box), indicative of infiltrated leukocytes, were further subdivided into Ly6G-positive or CD11b and Ly6C double-positive cells. EC Panx1 fl/fl, n = 6 mice; EC Panx1 Δ/Δ, n = 5 mice. *P < 0.05; Student’s t test.
in leukocyte infiltration, suggesting the importance of extracellular ATP/UTP degradation to adenosine in postischemic stroke inflammation (28, 29). More conclusively, our data show that deletion of endothelial Panx1 leads to a significant reduction in leukocyte infiltration into the ischemic hemisphere following 24-hour perfusion, with no significant differences in the relative amounts of the specific subsets of leukocytes, such as neutrophils and monocytes (30). These data suggest that endothelial Panx1 regulates passage of leukocytes from the venous system into the brain tissues in a non–subtype-specific manner following a cerebral ischemia/reperfusion injury; however, there are additional subsets of leukocytes that we have not examined, thus necessitating future evaluation.

Spreading depolarizations (SD) have been found to alter the blood-brain barrier, resulting in a breakdown of the EC-EC junctions due to increased MMP-9 activity, neuroinflammation, and injury-induced depolarizations, which — combined — can have negative effects on the ischemic and penumbra tissue (31). Recently, neuronal Panx1 has been implicated in regulating SD, where inhibition of the Panx1-P2X7 complex suppressed SD and neuroinflammation (32). Although CBF and neurovascular communication may regulate SD and SD recovery, it is unclear if cerebral endothelial Panx1 regulates SD. Furthermore, although the Panx1-P2X7 complex has been shown to be functionally relevant in neurons, it is unknown if P2X7 functionally complexes with Panx1 in ECs and if this complex is important for the role of the cerebral vasculature during an ischemic stroke injury. Further investigation of the potential roles and binding partners of cerebral endothelial Panx1 is necessary to determine if these neuronal effects are also present in the cerebral ECs.

Our data also demonstrate that EC Panx1 regulates cerebral arterial function. Cerebral arteries are predominantly regulated by myogenic reactivity, which maintains constant CBF rates despite fluctuations in MAP (14). The mechanism of myogenic reactivity in the cerebral circulation remains incompletely understood, but a number of published reports suggest that purinergic receptors play a strong role in regulating myogenic responses (18, 19), specifically the P2Y4 and P2Y6 isoforms (18). As purinergic receptors are activated by extracellular purines such as ATP/UTP and ADP/UDP, this raises the possibility that Panx1 channels might facilitate release of purines needed for receptor activation. In support of this hypothesis, our data show that treatment with apyrase, which degrades extracellular purines, or deletion of EC Panx1 results in a reduction in the myogenic tone development, which was not observed upon deletion of SMC Panx1. Interestingly, this reduction was due to changes in the active but not the passive diameter of cerebral arteries, indicating that the reduction was likely due to cell signaling and not to changes in the vessel structural properties. In line with these observations, inhibition of myogenic tone might also lead to reduced vasoconstriction, increased CBF within the cerebral vasculature, and improved stroke outcomes, although this remains to be tested. The mechanisms by which Panx1 channels in cerebral arterial ECs are activated also remains to be elucidated. Panx1 channels have been shown to be mechanosensitive, although the data is ambiguous as to whether Panx1 channels open in direct response to stretch themselves or if channel opening is mediated by additional stretch-sensing proteins (33, 34).

Myogenic tone development is a common regulatory mechanism in most peripheral resistance arteries, which raises an important question as to whether endothelial Panx1–dependent myogenic reactivity is unique to the cerebral arteries, and if it can be therapeutically targeted without alterations.
to the peripheral vasculature. Mice treated with carbenoxolone display significantly reduced myogenic tone development in resistance arteries in the cerebral and the mesenteric vasculature, as demonstrated in this work. However, carbenoxolone inhibits connexin 43 (Cx43) channels as well as Panx1 channels (35). Here, we utilized our inhibitor, spironolactone (25), and our transgenic EC Panx1–deleted mice and found that myogenic tone in mesenteric arteries was unaffected by the inhibition of Panx1 (but not Cx43) or the loss of EC Panx1, respectively. These data, along with previously published data, indicate that Cx43 may participate in myogenic tone development in mesenteric arteries, but more likely, EC Panx1 does not (27). Future studies should elucidate the feasibility of targeting differential myogenic responses between the cerebral vasculature and mesenteric arteries.

Blood pressure is regulated through SMC Panx1, which regulates α-adrenergic signaling (10), and mice specifically lacking smooth muscle Panx1 have been found to have a significant reduction in their MAP (10). Changes in overall blood pressure can impact postischemic stroke outcome; however, the role of EC Panx1 in blood pressure regulation and heart rate was previously unknown. Our data showed that neither MAP during the day when mice are at rest nor at night when mice are active were altered by deletion of endothelial Panx1. Additionally, heart rate was unchanged in mice lacking endothelial Panx1. These data suggest that EC Panx1 regulates cerebral myogenic tone and impacts ischemic stroke outcome independently of changes in peripheral blood pressure.

In summary, we show for the first time to our knowledge that EC Panx1 within the cerebral vasculature regulates pathways important to ischemic stroke outcomes. Leukocyte infiltration was significantly reduced following cerebral ischemic injury when Panx1 was deleted specifically from ECs. In addition, myogenic reactivity in cerebral arteries is regulated by EC Panx1, and deletion of EC Panx1 uniquely reduced myogenic tone development in cerebral arteries with no change in peripheral mesenteric reactivity or overall blood pressure. Together, these data indicate that endothelial Panx1 influences multiple vascular functions that influence the severity of the stroke phenotype and that differentially targeting EC Panx1 in the cerebral vasculature may be a novel strategy for improving outcomes following ischemic stroke.

Methods

Mice. Mice were fed a normal chow and housed under a 12-hour light/dark cycle. All mice were male and were used between 10 and 20 weeks of age. The genotypes include: C57Bl/6 purchased from Taconic; Panx1fl/fl/SMMHC Cre-ERT2+ (SMC Panx) (10); Panx1fl/fl/VeCad Cre-ER(T2+ (EC Panx) (11); and Panx1fl/fl/Cre–. Transgenic mice were injected for 10 days with vehicle (peanut oil; [fl/fl]) or tamoxifen (1 mg/kg/day) to delete Panx1 from the corresponding cell type (∆/∆). Panx1fl/fl/Cre– were injected with tamoxifen to serve as a tamoxifen control (Cre– Panx1 fl/fl).

IHC. For whole brain and isolated PCA sections, C57Bl/6 mice were anesthetized using methoxyflurane (Alfa Aesar) and transcardially perfused with heparinized PBS followed by 4% paraformaldehyde (PFA; MilliporeSigma) in PBS. Whole brains were then placed in 4% PFA for 24 hours at 4°C, followed by 48 hours in 30% sucrose in PBS, embedded in OCT compound, and flash frozen, and 10 μm sections were
obtained. PCAs were isolated from the brain, fixed in 4% PFA for 1 hour, and embedded in paraffin, and 5-μm cross sections were obtained. Whole brain sections were brought to room temperature and washed in PBS to remove excess OCT. PCA cross sections were subjected to paraffin removal and washing. Whole brain and PCA cross sections then underwent antigen retrieval (antigen unmasking solution, Vector), were blocked for 30 minutes, and were stained for Panx1 as previously described (4). Whole brain sections were stained with Panx1-CT antibody (1:200) (4), and neuronal-stained brains and isolated PCA sections were stained with Panx1-NT antibody (1:50; Cell Signaling Technology; catalog 91137). Neurons were stained using NeuN (MilliporeSigma; clone MAB377; 1:1,000). Control whole brains were stained with Rabbit IgG control Ab (25 μg/ml; catalog I-1000, Vector Laboratories). Anti–rabbit secondary F(ab)’2 antibody coupled to Alexa Fluor 568 (1:400; Invitrogen) was applied to all sections (except neuronal stained sections:

Figure 6. Myogenic tone in mesenteric arteries, mean arterial pressure, and heart rate are independent of EC Panx1. Pressure curves were run on third-order mesenteric arteries isolated from C57Bl/6 mice in the presence or absence of carbenoxolone (CBX; 50 μM; A–C), spironolactone (80 μM; D–F), or mesenteric arteries isolated from EC Panx1 fl/fl and Δ/Δ mice (G–I). Percent myogenic tone, active diameter, and passive diameter were analyzed for each group. Control (CBX), n = 5; CBX, n = 3; control (spironolactone), n = 3; spironolactone, n = 3; EC Panx1 fl/fl, n = 4; and EC Panx1 Δ/Δ, n = 6 mice. *P < 0.05. Two-way ANOVA/Sidak’s multiple comparisons post hoc test. Telemetry was used to collect average day and night mean arterial pressure (J) and heart rate (K) from EC Panx1 fl/fl and EC Panx1 Δ/Δ mice. No significant differences were found using Student’s t test.
Alexa Fluor 488 goat anti-mouse [NeuN] and Alexa Fluor 555 goat anti-rabbit [PanX1]) and then imaged using an Olympus FluoView 1000 as previously described (36).

**MCAO/reperfusion.** Three weeks following the last injection of tamoxifen, to ensure removal of tamoxifen from the system, mice underwent a 90-minute MCAO followed by a 24-hour reperfusion as previously described (37). Briefly, under anesthesia, a 6-0 filament was fed through the left external carotid artery and placed over the MCA to occlude the MCA for 90 minutes. Anesthesia was stopped once the MCA was occluded, and then mice were reanesthetized after 90 minutes to remove the suture. Twenty-four hours after removal of the suture, the brain was harvested, and 2-mm sections were stained with TTC to visualize the ischemic region vs. the remaining healthy tissue. Using ImageJ, infarct volume (corrected for edema) was calculated as: Percent Infarct volume = ([nonischemic hemisphere area − (ischemic hemisphere area − infarct area)] / nonischemic hemisphere area) × 100.

**Flow cytometry.** Flow cytometry was used to determine leukocyte infiltration into the brain (30). Mice were anesthetized using isoflurane and were transcardially perfused with 10 ml heparinized PBS, separated into ischemic vs. nonischemic hemispheres, and then placed into HBSS containing divalent cations (HBSS + Ca/Mg). To obtain a single cell suspension, hemispheres were pushed through the plunger of a 5-ml syringe, and the filter was rinsed continuously with HBSS + Ca/Mg. The samples were then centrifuged at 300 g at 4°C for 5 minutes, and the pellet was resuspended in HBSS + Ca/Mg containing liberase TL (2 U/ml; MilliporeSigma). Samples were digested for 1 hour at 37°C with continuous shaking at 300 rpm and then filtered through a 70-μm filter. The filter was then rinsed with 3 ml HBSS containing DNase1 (666 U/ml; MilliporeSigma) and FBS (10%), followed by 15 ml of wash buffer (HBSS containing 10% FBS). Following centrifugation at 300 g at 18°C for 5 minutes, samples were resuspended in room-temperature, 25% density gradient medium (DGM) (for 100% DGM: mix 1 part 1.5M NaCl and 9 parts Percoll [MilliporeSigma]; diluted to 25% by addition of HBSS containing 3% FBS). The samples were then centrifuged at 600 g at 10°C for 20 minutes using the lowest acceleration rate of the Sorvall ST16R centrifuge (with Thermo Fisher Scientific rotor 75003181) and no brake. The layer of myelin was carefully aspirated, and the remaining pellet was rinsed in washing buffer, moved to a clean tube, and centrifuged at 300 g at 10°C for 5 minutes. Cell pellet was resuspended in Yellow live/dead cell stain (Thermo Fisher Scientific) per manufactures directions, incubated at 4°C for 15 minutes, and then centrifuged at 300 g at 10°C for 5 minutes. The cell pellet was then resuspended in wash buffer and blocked using anti–murine CD16/32 FC receptor (2.5 μg/ml; Invitrogen) for 10 minutes at 4°C. Fluorophore-conjugated primary antibodies were then added to the cells and incubated for 20 minutes at 4°C in the dark. The following antibodies were used; FITC anti–mouse CD45 Ab (clone 30-F11; 5 μg/ml; BioLegend), APC/Cy7 anti–mouse Ly6G Ab (clone 1A8; 1 μg/ml; BioLegend), Brilliant Violet 421 anti–mouse/human CD11b Ab (clone M1/70; 2 μg/ml; BioLegend), and PE anti–mouse Ly6C Ab (clone HK1.4; 1 μg/ml; BioLegend). Cells were then rinsed in FACS Buffer (PBS containing 3% FBS), centrifuged at 400 g at 4°C for 7 minutes, and resuspended in FACS buffer. All samples were then analyzed with the Cytek FACSCalibur benchtop analyzer, and data were analyzed using FlowJo v10. Gates were determined using single-stained UltraComp eBeads (eBioscience), per manufactures directions, and fluorescence minus one (FMO) control samples, which contained all fluorescent probes except one.

**Pressure myography.** Freshly isolated PCAs and superior cerebellar arteries (SCAs), MCAs, or third order mesenteric arteries were placed into ice-cold Krebs-HEPES solution containing (in ml) NaCl 118.4, KCl 4.7, MgSO4 1.2, NaHCO3 4, KH2PO4 1.2, CaCl2 2, Heps 10, and glucose 6. The vessels were then mounted in a pressure arteriograph (Danish MyoTechnology) with the lumen filled with Krebs-HEPES solution. The vessels were pressurized to 80 mmHg and heated to 37°C for 30 minutes. For experiments treated with pharmacological inhibitors, lumen and bath solutions were changed to contain the desired concentration of drug or control diluent and allowed to equilibrate for 30 minutes. Myogenic curves were completed by increasing the luminal pressure from 20–120 mmHg in 20-mmHg increments to obtain the active diameter of the vessel. The pressure steps were then repeated after washing with a Ca2+-free Krebs-HEPES solution supplemented with 1 mM EGTA and 10 μM sodium nitroprusside to obtain maximal passive diameters for each pressure. Myogenic tone values are calculated as: ([passive diameter – active diameter] / passive diameter) × 100.

**Radiotelemetry.** Ten- to 12-week-old mice were implanted with radiotelemetry units (Data Sciences International [DSI]) as previously described (10, 38). Briefly, while under isoflurane anesthesia, the catheter of the radiotelemetry unit was placed in the left carotid artery and advanced toward the heart until resistance was felt.
The radiotransmitter was then placed in a s.c. pouch on the right flank. Mice were allowed to recover for 5 days. Blood pressure was then continuously recorded for 7 days.

Statistics. Data were analyzed using Prism 7 software (GraphPad Software Inc.) and displayed in mean ± SEM. Two-tailed Student’s t tests or 1-way ANOVA followed by Tukey’s multiple comparisons post hoc tests were used where appropriate. Two-way ANOVA followed by Sidak’s multiple comparisons post hoc tests were used for pressure myography experiments. P < 0.05 was considered to be statistically significant.

Study approval. All mice and procedures were approved by the University of Virginia School of Medicine ACUC.

Author contributions
MEG designed the research project, conducted experiments, analyzed and interpreted the results, and wrote and approved the manuscript. SAE designed the research project and conducted myogenic tone experiments. JL performed experiments associated with stroke procedures. HMB conducted flow cytometry experiments and analyzed blood pressure data. SML, JTB, and TJJ performed myogenic tone experiments. RPG and MKP performed IHC studies. ZZ and BEI designed the project and wrote and approved the manuscript. All authors read and provided comments on the manuscript.

Acknowledgments
The authors thank the members of the Pannexin Interest Group at the University of Virginia for their aid and input throughout the development of this work, as well as Alexander S. Keller, Leon J. DeLalio, and T.C. Stevenson Keller IV for critical feedback. The authors also thank the Flow Cytometry Facility at the University of Virginia School of Medicine for their assistance with flow cytometry experiments and the University of Virginia Histology core for processing vessels and brains for sectioning and mounting. This work was supported by NIH training grant HL007284 (MEG), NIH F32 HL131399 (MEG), NIH P01 HL120840 (BEI), the Robert M. Epstein Professorship endowment, University of Virginia (ZZ), and NCI P30 CA044579-23 (Flow Cytometry Center grant).

Address correspondence to: Brant E. Isakson, P.O. Box 801394, Charlottesville, Virginia 22908, USA. Phone: 434.924.2093; Email: brant@virginia.edu.


